Merck KGAA, which has been involved in gene and cell therapy manufacturing tools and services for close to three decades, is ramping up to tap into emerging opportunities in these exciting new areas of medicine.
The German multinational, which has been building on the expertise that the $17bn acquisition of Sigma-Aldrich brought with it in areas like gene editing, has recently been granted